Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Decreases By 80.8%

Tharimmune, Inc. (NASDAQ:THARGet Free Report) was the target of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 95,600 shares, a decline of 80.8% from the October 31st total of 496,900 shares. Based on an average daily trading volume, of 1,180,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 6.6% of the shares of the stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC bought a new stake in Tharimmune, Inc. (NASDAQ:THARFree Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned about 2.06% of Tharimmune at the end of the most recent quarter. Institutional investors own 1.16% of the company’s stock.

Tharimmune Trading Up 3.5 %

Shares of NASDAQ:THAR traded up $0.08 during midday trading on Wednesday, hitting $2.38. 26,383 shares of the stock were exchanged, compared to its average volume of 359,927. Tharimmune has a twelve month low of $1.84 and a twelve month high of $16.20. The company has a 50 day moving average price of $2.37 and a 200-day moving average price of $3.16.

Tharimmune Company Profile

(Get Free Report)

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).

Read More

Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.